Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Edoxaban, a Novel Oral Factor Xa Inhibitor.
CONCLUSIONS: Edoxaban is a safe and effective anticoagulant to reduce the risk of stroke in patients with NVAF and for the treatment of VTE. PMID: 25855704 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - April 8, 2015 Category: Drugs & Pharmacology Authors: Minor C, Tellor KB, Armbruster AL Tags: Ann Pharmacother Source Type: research

A prospective study investigating the causes of warfarin under-utilization in Chinese patients
Conclusion Patients with CHA2DS2-VASc scores ≥1 who were admitted with NVAF were under prescribed warfarin, and 138 patients were not treated with either warfarin or other antithrombotic therapies. In conclusion, a more aggressive approach for stroke prevention in NVAF patients is required.
Source: International Journal of Clinical Pharmacy - August 2, 2016 Category: Drugs & Pharmacology Source Type: research

The Role of Colchicine in the Prevention of Cerebrovascular Ischemia.
CONCLUSION: Inflammatory pathways seem to be key mediators in the development of atherosclerotic process, atheromatous plaque destabilization and thromboembolism. Colchicine as a novel therapeutic agent could be a safe and effective inhibitor of the inflammation cascade in patients with extra- or intracranial atherosclerosis or arteriolosclerosis, resulting in reduced vascular events. PMID: 29336246 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 15, 2018 Category: Drugs & Pharmacology Authors: Tsivgoulis G, Katsanos AH, Giannopoulos G, Panagopoulou V, Jatuzis D, Lemnens R, Deftereos S, Kelly PJ Tags: Curr Pharm Des Source Type: research

The protective mechanisms of polydatin in cerebral ischemia.
Abstract The prevalence of stroke is high in both developing and developed nations. It causes a heavy social and financial burden to the sufferers and their caregivers. Thrombolytic therapy is the only pharmacological treatment available for stroke. However, thrombolytic agents do not provide substantial improvement on long term motor and cognitive disabilities. Thus, there is a need to explore for new compounds that can halt or reverse the deterioration of neurons in the stroke patients' brain. Polydatin, a precursor of resveratrol, is a natural stilbene commonly found in food. This review article describes how d...
Source: European Journal of Pharmacology - October 29, 2018 Category: Drugs & Pharmacology Authors: Tang KS, Tan JS Tags: Eur J Pharmacol Source Type: research

NK cells in cerebral ischemia
Publication date: January 2019Source: Biomedicine & Pharmacotherapy, Volume 109Author(s): Chen Chen, Qi-Di Ai, Shi-Feng Chu, Zhao Zhang, Nai-Hong ChenAbstractAs a vital cell type in immune system and infiltrating cells in ischemic brain, NK cells can bridge the crosstalk between immune system and nervous system in stroke setting. The mechanism of action of NK cells is complicated, involving direct and indirect actions. NK cells are closely associated with poststroke inflammation, immunodepression and infections. The excessive inflammatory response in ischemic brain is one of the important causes for aggravating cerebral is...
Source: Biomedicine and Pharmacotherapy - November 4, 2018 Category: Drugs & Pharmacology Source Type: research

NK cells in cerebral ischemia.
Abstract As a vital cell type in immune system and infiltrating cells in ischemic brain, NK cells can bridge the crosstalk between immune system and nervous system in stroke setting. The mechanism of action of NK cells is complicated, involving direct and indirect actions. NK cells are closely associated with poststroke inflammation, immunodepression and infections. The excessive inflammatory response in ischemic brain is one of the important causes for aggravating cerebral ischemic injury. Besides the inflammation induced by ischemia itself, thrombolytic drug tissue plasminogen activator (tPA) administration coul...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 3, 2018 Category: Drugs & Pharmacology Authors: Chen C, Ai QD, Chu SF, Zhang Z, Chen NH Tags: Biomed Pharmacother Source Type: research

Association between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study
Clin Pharmacol Ther. 2021 Jul 19. doi: 10.1002/cpt.2369. Online ahead of print.ABSTRACTConcomitant use of direct oral anticoagulants (DOACs) and medications with inhibition/induction effect on P-gp/CYP3A might increase risk of bleeding/treatment failure, respectively. We designed a nested case-control study within a Clalit cohort of atrial fibrillation (AF) patients and a cohort of venous thromboembolic patients, new users of a DOAC (1.1.2010-24.8.2020). Propensity scores were constructed from demographic, clinical and medications at cohort entry. Each case of: 1) serious bleeding event; 2) stroke/systemic emboli (SE) in A...
Source: Clinical Pharmacology and Therapeutics - July 21, 2021 Category: Drugs & Pharmacology Authors: Naomi Gronich Nilli Stein Mordehcai Muszkat Source Type: research

Role of the renin-angiotensin system in NETosis in the coronavirus disease 2019 (COVID-19)
Biomed Pharmacother. 2022 Feb 14;148:112718. doi: 10.1016/j.biopha.2022.112718. Online ahead of print.ABSTRACTMyocardial infarction and stroke are the leading causes of death in the world. Numerous evidence has confirmed that hypertension promotes thrombosis and induces myocardial infarction and stroke. Recent findings reveal that neutrophil extracellular traps (NETs) are involved in the induction of myocardial infarction and stroke. Meanwhile, patients with severe COVID-19 suffer from complications such as myocardial infarction and stroke with pathological signs of NETs. Due to the extremely low amount of virus detected i...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 17, 2022 Category: Drugs & Pharmacology Authors: Qingguang Zhang Shang Ling Kaili Hu Jun Liu Jin-Wen Xu Source Type: research

Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial Fibrillation
ConclusionsASDs were significantly associated with all-cause mortality in patients with NVAF taking OACs.
Source: Drugs in R&D - July 19, 2022 Category: Drugs & Pharmacology Source Type: research

Combination Approaches to Attenuate Hemorrhagic Transformation After tPA Thrombolytic Therapy in Patients with Poststroke Hyperglycemia/Diabetes.
Abstract To date, tissue type plasminogen activator (tPA)-based thrombolytic stroke therapy is the only FDA-approved treatment for achieving vascular reperfusion and clinical benefit, but this agent is given to only about 5% of stroke patients in the USA. This may be related, in part, to the elevated risk of symptomatic intracranial hemorrhage, and consequently limited therapeutic time window. Clinical investigations demonstrate that poststroke hyperglycemia is one of the most important risk factors that cause intracerebral hemorrhage and worsen neurological outcomes. There is a knowledge gap in understanding the ...
Source: Advances in Pharmacology - October 15, 2014 Category: Drugs & Pharmacology Authors: Fan X, Jiang Y, Yu Z, Yuan J, Sun X, Xiang S, Lo EH, Wang X Tags: Adv Pharmacol Source Type: research

Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin
We describe the first case report, to our knowledge, documenting a drug interaction between phenytoin and dabigatran by using laboratory measurements of dabigatran serum concentrations. A 45‐year‐old African‐American man was admitted to the inpatient cardiology service following defibrillations from his implantable cardioverter defibrillator. The patient was evaluated and received appropriate antitachycardia pacing for atrial tachyarrhythmias for an episode of ventricular tachycardia (VT), and antiarrhythmic therapy with sotalol was initiated to reduce both his AF and VT burden. On review of the patient's medications...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 5, 2016 Category: Drugs & Pharmacology Authors: Barbara S. Wiggins, Amanda Northup, Dominic Johnson, Jeffrey Senfield Tags: Case Report Source Type: research

Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study
Conclusions The use of dabigatran appears to be similar to warfarin in preventing the formation of intracardiac thrombus. Trial Registration Clinicaltrials.gov NCT01868243.
Source: Drugs in R&D - February 18, 2016 Category: Drugs & Pharmacology Source Type: research